<SEC-DOCUMENT>0001641172-25-025258.txt : 20250822
<SEC-HEADER>0001641172-25-025258.hdr.sgml : 20250822
<ACCEPTANCE-DATETIME>20250822171522
ACCESSION NUMBER:		0001641172-25-025258
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250822
DATE AS OF CHANGE:		20250822

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DSS, INC.
		CENTRAL INDEX KEY:			0000771999
		STANDARD INDUSTRIAL CLASSIFICATION:	PAPERBOARD CONTAINERS & BOXES [2650]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				161229730
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-50256
		FILM NUMBER:		251247175

	BUSINESS ADDRESS:	
		STREET 1:		275 WIREGRASS PKWY
		CITY:			WEST HENRIETTA
		STATE:			NY
		ZIP:			14586
		BUSINESS PHONE:		585 232 1500

	MAIL ADDRESS:	
		STREET 1:		275 WIREGRASS PKWY
		CITY:			WEST HENRIETTA
		STATE:			NY
		ZIP:			14586

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DOCUMENT SECURITY SYSTEMS INC
		DATE OF NAME CHANGE:	20030326

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW SKY COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THOROUGHBREDS USA INC
		DATE OF NAME CHANGE:	19861118

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chan Heng Fai Ambrose
		CENTRAL INDEX KEY:			0001261725
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		2601 INSLAND PLACE TOWER
		STREET 2:		510 KINGS RD N POINT
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999999999

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAN FAI
		DATE OF NAME CHANGE:	20030828
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001493152-25-005754</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Chan Heng Fai Ambrose -->
          <cik>0001261725</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>21</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.02 per share</securitiesClassTitle>
      <dateOfEvent>08/20/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0000771999</issuerCIK>
        <issuerCUSIP>26253C201</issuerCUSIP>
        <issuerName>DSS, INC.</issuerName>
        <address>
          <com:street1>275 Wiregrass Pkwy,</com:street1>
          <com:city>West Henrietta</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>14586</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Heng Fai Ambrose Chan</personName>
          <personPhoneNum>011 65 6333 9181</personPhoneNum>
          <personAddress>
            <com:street1>9 Temasek Boulevard #16-04, Suntec Tower</com:street1>
            <com:city>Singapore</com:city>
            <com:stateOrCountry>U0</com:stateOrCountry>
            <com:zipCode>038989</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001261725</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Heng Fai Ambrose Chan</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>6730059.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>6730059.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>6730059.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>69.6</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) The beneficial ownership of Heng Fai Ambrose Chan includes 6,730,059 shares of common stock, consisting of (a) 1,002,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Ambrose Chan; (b) 1,184,475 shares of common stock held by Heng Fai Ambrose Chan directly; (c) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; (d) 2,581,268 shares of common stock and debt convertible into 581,395 shares of common stock held by Alset Inc.; and (e) 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001750106</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Alset Inc.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>4542606.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>4542606.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>4542606.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>47.0</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>(1) Includes 2,581,268 shares of common stock and debt convertible into 581,395 shares of common stock held directly by Alset Inc.; 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; and 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Global Biomedical Pte. Ltd.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>311634.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>311634.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>311634.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.4</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001660984</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Alset International Limited</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>1379943.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>1379943.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>1379943.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>15.2</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 9,092,518 shares of the common stock of the Issuer outstanding as of August 21, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.02 per share</securityTitle>
        <issuerName>DSS, INC.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>275 Wiregrass Pkwy,</com:street1>
          <com:city>West Henrietta</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>14586</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Heng Fai Ambrose Chan</filingPersonName>
        <principalBusinessAddress>c/o Alset International Limited, 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038987</principalBusinessAddress>
        <principalJob>Chairman and Chief Executive Officer, Alset International Limited, 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038987</principalJob>
        <citizenship>Singapore</citizenship>
      </item2>
      <item3>
        <fundsSource>On August 20, 2025, the Issuer issued a convertible promissory note (the "Convertible Note") to Alset Inc. in the amount of $500,000.00. Under the terms of the Convertible Note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of $0.86 per share.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>On August 20, 2025, the Issuer issued a convertible promissory note (the "Convertible Note") to Alset Inc. in the amount of $500,000.00. Under the terms of the Convertible Note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of $0.86 per share.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Heng Fai Ambrose Chan: 6,730,059, 69.6% Alset Inc.: 4,542,606, 47.0% Global Biomedical Pte. Ltd.: 311,634, 3.4% Alset International Limited: 1,379,943, 15.2%</percentageOfClassSecurities>
        <numberOfShares>Heng Fai Ambrose Chan: 6,164,664 Alset Inc.: 4,542,606 Global Biomedical Pte. Ltd.: 311,634 Alset International Limited: 1,379,943</numberOfShares>
        <transactionDesc>None.</transactionDesc>
      </item5>
      <item7>
        <filedExhibits>Joint Filing Agreement between Heng Fai Chan, Global Biomedical Pte. Ltd. and Alset Inc., incorporated by reference to Amendment No. 13 to the Schedule 13D filed on September 20, 2021.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Heng Fai Ambrose Chan</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, an Individual</title>
          <date>08/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alset Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Chief Executive Officer, Alset Inc.</title>
          <date>08/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Global Biomedical Pte. Ltd.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Director, Global Biomedical Pte. Ltd.</title>
          <date>08/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alset International Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Chief Executive Officer, Alset International Limited</title>
          <date>08/22/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
